Close
Smartlab Europe
Inizio Ignite

Drug Research

InnoCore, Allergan to develop new drug delivery products for ophthalmic diseases

Netherland-based injectable drug delivery products producer InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan (AGN), to develop new medicines for ophthalmic diseases. The deal will see the companies expand their existing...

Adimab, Celgene form drug discovery partnership

Adimab signed a multi-target discovery agreement with Celgene Corporation, pursuant to which, Adimab will use its proprietary discovery and optimization platform to generate fully human antibodies against multiple targets. Under the terms of the agreement,...

Adimab, Innovent collaborate on discovery, commercialization of antibody-based therapeutic

Adimab and Innovent have collaborated to discover, develop and commercialise an antibody-based therapeutic, using Adimab antibody discovery and optimization platform, against a selected specific target. All initial product development activities such as cell line development,...

Supernus to launch Trokendi extended release formulation to treat epilepsy

Specialty pharmaceutical company Supernus Pharmaceuticals is set to launch once-daily extended release formulation of topiramate, Trokendi XR, to treat epilepsy following the final FDA approval. Approved for use as recommended in the agreed-upon labeling, Trokendi...

Takeda announces availability of type 2 diabetes drugs in US

Takeda Pharmaceutical Company has announced the availability of NESINA (alogliptin) and fixed-dose combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) by prescription in the US. The FDA approved medications are indicated as...

Amedra re-launches Adrenaclick to treat anaphylaxis

Amedra Pharmaceuticals has re-launched a single-dose epinephrine auto-injector Adrenaclick for people with increased risk of anaphylaxis in both 0.15mg and 0.30mg strengths. Potentially life-threatening allergic reaction, Anaphylaxis onsets rapidly and may cause severe swelling, breathing...

Eisai to market and distribute Belviq weight management therapy in US

Eisai has announced the availability of Belviq (lorcaserin HCl) CIV tablets in the US, which is designed for chronic weight management in adults who are overweight with a comorbidity or obesity. Indicated for people with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »